What’s New
Explore latest events, medical insights and trends.
ATS 2026 Highlights: COPD & Asthma Biologic Insights
Explore ATS 2026 key sessions on dupilumab, COPD biologics, FeNO biomarkers, and asthma remission. Real-world evidence for HCPs
One Rare – Order. Collect. Track.
We're excited to announce OneRare, our streamlined approach to ordering DBS (Dried Blood Spot) kits for rare disease diagnostics. Built on the same trusted testing you know, OneRare introduces an enhanced digital ordering workflow designed to reduce administrative burden and improve turnaround times.
AAD 2026: Dermatology Updates Denver
AAD 2026 post-congress: Complete systemic therapy update. Multi-indication clinical data for inflammatory dermatological conditions.
Beyfortus® Real-World Effectiveness: Meta-Analysis
Systematic review shows Beyfortus® reduces RSV hospitalizations by 83% and ICU admissions by 81% in real-world infant immunization programs.
Expert consensus on the burden of RSV disease and the utility of nirsevimab for disease prevention and
protection of infants
Dupilumab in Chronic Spontaneous Urticaria: Evidence from the Phase 3 LIBERTY-CSU CUPID Trials
Chronic spontaneous urticaria (CSU) creates substantial patient burden through persistent wheals, angioedema, and debilitating itch that severely disrupts daily functioning. Emerging evidence positions type 2 inflammation as a driver of CSU pathogenesis. IL-4 plays a particularly crucial role by stimulating excessive IgE production and promoting formation of IgG anti-IgE autoantibodies—both pathways that trigger mast cell degranulation and subsequent CSU symptoms. This mechanistic understanding has opened therapeutic opportunities targeting type 2 inflammatory pathways for patients who remain symptomatic despite standard antihistamine therapy.
Request-form
